Puma Biotechnology Inc (PBYI) News
Filter PBYI News Items
PBYI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PBYI News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PBYI News From Around the Web
Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.
Best Value Stocks to Buy for January 6thAHT, PBYI and CWD made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 6, 2024. |
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)LOS ANGELES, January 03, 2025--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 24,375 shares of Puma common stock to two new non-executive employees. |
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
US Penny Stocks With Promise: 3 Picks Under $200M Market CapAs the U.S. stock market experiences a downturn, with major indices like the Dow Jones and Nasdaq Composite sliding, investors are increasingly looking for opportunities beyond large-cap tech stocks. Penny stocks, although a somewhat outdated term, continue to offer potential growth opportunities in smaller or newer companies when backed by strong financial health. These investments can present a mix of affordability and growth potential, making them an intriguing option for those seeking... |
Puma Biotechnology Stock Rises 24% in 3 Months: Here's WhySales of PBYI's sole-marketed drug, Nerlynx exceeded management's expectations in the third quarter. Also, the acquisition of alisertib holds promise. |
Is Bristol Myers Squibb (BMY) Stock Undervalued Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
Best Momentum Stocks to Buy for December 24thPBYI, DDS and NJR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 24, 2024. |
Best Value Stocks to Buy for December 24thPBYI, DDS and PINC made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 24, 2024. |
With 49% stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) seems to have captured institutional investors' interestKey Insights Significantly high institutional ownership implies Puma Biotechnology's stock price is sensitive to their... |
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 MutationLOS ANGELES, December 23, 2024--NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat. 2A. |